Search
Showing results for "1"
Research
Persistent activation of interlinked type 2 airway epithelial gene networks in sputum-derived cells from aeroallergen-sensitized symptomatic asthmaticsOur findings provide new insight into the molecular mechanisms operative at baseline in the airway mucosa in atopic asthmatic with natural aeroallergen exposure
Contact us If you'd like to get in touch, please contact us by phone or email. Phone: 0400 450 240 Email: vtg@thekids.org.au Respiratory Syncytial
Strengths-based, tiered, accessible, resources and supports (STARS) for Kids for parent, carers and their children.
News & Events
New research on youth-onset type 2 diabetes in northern AustraliaExplore new research on youth-onset diabetes at The Kids' Institute, uncovering insights to improve health outcomes for young patients in Northern Australia.
News & Events
Telehealth can support families with their goalsIn this blog, Speech Pathology Clinical Lead Aria May looks at telehealth and how it can support children and families with their therapy goals.
In 2014, Wesfarmers committed $5 million over 4 years to The Kids' research to set up the Wesfarmers Centre of Vaccines and Infectious Diseases.
Research
DETECT Schools Study Protocol: A Prospective Observational Cohort Surveillance Study Investigating the Impact of COVID-19 in Western Australian SchoolsAmidst the evolving COVID-19 pandemic, understanding the transmission dynamics of the SARS-CoV-2 virus is key to providing peace of mind for the community and informing policy-making decisions. While available data suggest that school-aged children are not significant spreaders of SARS-CoV-2, the possibility of transmission in schools remains an ongoing concern, especially among an aging teaching workforce. Even in low-prevalence settings, communities must balance the potential risk of transmission with the need for students' ongoing education.
Kids Rehab WA is an integrated team of clinicians and researchers who deliver and research therapies for children with acquired or congenital neurological impairments, leading to improved outcomes for children and their families.
Research
An initial health economic evaluation of the potential benefits gained by reducing late effects in paediatric brain cancer survivorsRaelene Nick Endersby Gottardo BSc (Hons) PhD MBChB FRACP PhD Brainchild Fellow; Co-Head, Brain Tumour Research Head of Paediatric and Adolescent
Research
Clinical experience with SUBA-itraconazole at a tertiary paediatric hospitalItraconazole remains a first-line antifungal agent for certain fungal infections in children, including allergic bronchopulmonary aspergillosis (ABPA) and sporotrichosis, but poor attainment of therapeutic drug levels is frequently observed with available oral formulations. A formulation of 'SUper BioAvailability itraconazole' (SUBA-itraconazole; Lozanoc®) has been developed, with adult studies demonstrating rapid and reliable attainment of therapeutic levels, yet paediatric data are lacking.